Table 3 Correlation between SNF5 expression and different clinicopathologic features in ECs
From: Expression and potential role of SNF5 in endometrial carcinoma
Characteristics | Samples (n) | SNF5 expression | P-value | |
|---|---|---|---|---|
Positive | Negative | |||
Ages | ||||
āāā„ā50 | 40 | 25 | 15 | 0.318 |
āā<ā50 | 6 | 5 | 1 | Ā |
Pathologic subtype | ||||
āEndometrioid | 40 | 28 | 12 | 0.079 |
āNon-endometrioid | 6 | 2 | 4 | Ā |
FIGO stage | ||||
āI | 31 | 20 | 11 | 0.761 |
āII | 8 | 6 | 2 | Ā |
āIII | 7 | 4 | 3 | Ā |
Histological grade | ||||
āG1 | 18 | 14 | 4 | 0.152 |
āG2 and G3 | 28 | 16 | 12 | Ā |
Myometrial invasion | ||||
āāā„ā1/2 | 15 | 12 | 3 | 0.626 |
āā<ā1/2 | 31 | 18 | 13 | Ā |
Lymphatic metastasis | ||||
āYes | 7 | 4 | 3 | 0.143 |
āNo | 39 | 26 | 13 | Ā |
ER expression | ||||
āpositive | 29 | 19 | 10 | 0.956 |
ānegative | 17 | 11 | 6 | Ā |
PR expression | ||||
āpositive | 31 | 23 | 8 | 0.024* |
ānegative | 15 | 6 | 9 | Ā |